Native Lawsuit Explained: What the Deodorant Case Revealed and Why PFAS Scrutiny Is Still Hanging Over the Brand
When people search Native lawsuit, they are usually looking at the consumer case tied to Native deodorant and the wider questions it raised about clean beauty, odor-protection claims, and PFAS in personal-care products. Native’s own site still positions the brand around deodorant, body, hair, skincare, hand soap, and toothpaste, and it markets those products as “clean,” “simple,” and “effective,” including a promise of “72 hr odor protection” on the deodorant side. That makes the legal fight easy to understand. Once a brand builds trust around purity and performance, any suggestion that the promise may overreach gets attention fast.
Why this lawsuit got traction so quickly
The Native story is crucial because it sits at the intersection of two things consumers care about deeply: product safety and honest marketing. Native’s packaging and website language lean hard into the idea that the products skip unwanted ingredients and still work well, which is exactly the sort of claim that invites scrutiny when buyers feel the experience does not match the label. In the federal case, plaintiff Ashton Hernandez said Native deodorant was sold as “clinically proven 72-hour odor protection,” that she paid $14 at Target in March 2024, and that the product did not deliver the multi-day result she believed she had bought. The complaint also alleged that Native’s instructions told users to reapply during the day, which the plaintiff argued cut against the long-wear claim.
That part of the dispute is not just about one deodorant rather it is about the way premium personal-care brands sell confidence. A bottle can cost more than a generic competitor partly because the label suggests science-backed performance, and that is where lawsuits often begin. In this case, the court record shows the plaintiff framed the ad claim as misleading, while the defendant pointed to a clinical study document it said existed. The judge’s opinion turned on the pleading itself, not on a full trial over whether the deodorant worked in the real world.
What the court actually decided
The key legal fact is simple. The federal court in New York dismissed the proposed class action on April 9, 2025. Judge Denise L. Cote granted Zenlen’s motion to dismiss and directed the clerk to enter judgment for the defendant and close the case. The opinion says the plaintiff’s amended complaint still alleged, in essence, that Native’s claim was false because the company had “never” clinically tested the deodorant, but that allegation was unsupported and conflicted with the plaintiff’s own later argument that a study existed but did not prove what the marketing suggested.
That sequence is important because it shows how quickly a consumer case can narrow. The judge did not say the marketing language was ideal. She said the complaint did not plead a plausible misleading statement claim well enough to survive dismissal. In simple words, the court found the pleading too contradictory and too thin to move forward. For readers tracking the brand, that means the best-known deodorant case ended before discovery could fully test the competing narratives.
Why PFAS changed the conversation
The lawsuit did not appear in a vacuum. It landed in a moment when PFAS had become one of the most watched topics in consumer litigation and cosmetics regulation. According to the EPA, people can be exposed to PFAS in multiple ways, including by using products made with PFAS or packaged in materials containing them, and it specifically lists certain shampoo, dental floss, and cosmetics among personal-care examples. EPA also says scientific studies show certain PFAS exposures may be linked to reproductive effects, developmental effects, some cancers, reduced immune response, hormone interference, and higher cholesterol.
That broader scientific backdrop is one reason personal-care brands get pulled into litigation faster than they once did. The FDA’s December 2025 report on PFAS in cosmetics found that, based on mandatory product listing data submitted as of August 30, 2024, 51 different PFAS were used in 1,744 cosmetic formulations in the U.S., which represented 0.41% of the 430,134 registered cosmetic products in the agency’s dataset. The FDA also said the report exposed major data gaps, including limited data on use levels, limited dermal and oral absorption data, missing mechanistic information, and a lack of dermal toxicity data.
Those numbers do not prove Native products contained PFAS, but they do show why the subject became legally combustible. If regulators are still mapping how PFAS are used in cosmetics at all, then a consumer-facing brand built around “clean” positioning has a harder time escaping public suspicion once the phrase forever chemicals enters the conversation. The FDA’s report also notes that PFAS are used in cosmetics for properties like water repellency, smooth texture, and film formation, which explains why the chemistry appears in product categories that are designed to feel silky, last longer, or spread more evenly.
What the science says about skin exposure
One of the strongest reasons PFAS claims keep showing up in beauty disputes is that the old assumption about skin absorption is getting weaker. Researchers at the University of Birmingham reported that, in a study using 3D human skin models, 15 of 17 PFAS tested showed substantial dermal absorption of at least 5% of the exposure dose. They found that PFOA reached 13.5% absorption into the bloodstream, with another 38% retained in skin tissue for possible later uptake. The study also found that a shorter-chain PFAS, perfluoropentanoic acid, was absorbed at about 59%.
We need to be serious about this research because it weakens the easy defense that anything on the skin stays on the skin. For years, cosmetic companies could lean on the idea that dermal exposure was minor compared with ingestion or inhalation. The newer data suggests the skin route deserves much more attention, especially when a product stays in contact with the body daily. That does not automatically create liability for every brand, but it does raise the evidentiary bar for companies that market themselves as free from controversial chemicals while operating in a category where those chemicals may still appear.
Where Native stands now
As of the latest court record I found, the deodorant case is closed. The more speculative PFAS-related Native shampoo discussion has been described in consumer-law coverage as an investigation rather than a filed class action, which means the legal picture is less concrete there than it was in the deodorant case. The careful way to read that is straightforward. One Native lawsuit has already been dismissed, while the PFAS angle remains a broader consumer and regulatory concern rather than a finished courtroom fight.
That distinction counts for anyone reading headlines too fast. A dismissed false-advertising case says one plaintiff could not clear the pleading stage. It does not say every product claim from the brand was validated, and it does not settle the wider PFAS question in cosmetics. Meanwhile, the FDA has already told consumers and manufacturers that the agency’s PFAS assessment found serious data gaps, which is exactly the kind of regulatory language that keeps the issue alive even after a headline lawsuit cools off.
The real lesson for consumers and brands
The Native lawsuit is best understood as a warning shot, not a final verdict on an entire product line. For consumers, the case shows why glossy claims like clinically proven and 72-hour protection deserve a second look when they are attached to everyday products that sit directly on skin. For brands, it shows the risk of building a premium story on language that invites scientific challenge, especially when a product category is already under scrutiny for PFAS, ingredient transparency, and dermal exposure questions. Native may still sell itself as clean and effective, but the legal and scientific climate around personal care has changed, and the old playbook of making big promises with thin backup carries more risk than it once did.
The practical takeaway of the Native lawsuit is: the deodorant case was dismissed, the PFAS concern remains part of a much bigger cosmetics story, and the science around skin exposure has moved far enough that brands can no longer treat “clean” as a shield against legal pressure. In this corner of the personal-care market, the gap between marketing and proof has become the whole game.
